View Financial HealthOnco-Innovations 배당 및 자사주 매입배당 기준 점검 0/6Onco-Innovations 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-7.8%자사주 매입 수익률총 주주 수익률-7.8%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Jan 25Onco-Innovations Limited announced that it expects to receive CAD 2 million in fundingOnco-Innovations Limited announced a non-brokered private placement of up to 2,272,727 units at a price of CAD 0.88 per unit for aggregate gross proceeds of up to CAD 1,999,999.76 on January 23, 2026. Each unit shall consist of one common share and one-half of one common share purchase warrant, with each warrant entitling the holder to purchase one share at an exercise price of CAD 1.10 for a period of 36 months. The company also intends to issue shares equal to 1% of the total of shares issued in the private placement to an arm's-length third party as an administrative fee for its assistance with the private placement. In connection with the private placement, the company may pay finders' fees and/or issue finders' warrants on the same terms as the warrants to eligible parties which have assisted by introducing subscribers to the private placement. Closing of the private placement is subject to certain conditions, including, but not limited to, the receipt of all necessary regulatory and other approvals. All securities issued pursuant to the private placement will be subject to a hold period of four months and one day pursuant to applicable securities laws.공시 • Nov 22Onco-Innovations Advances Optimization and Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services to Support Future Phase 1 Clinical StudiesOnco-Innovations Limited announced that its manufacturing partner, Dalton Pharma Services ("Dalton"), has initiated process optimization and intermediate scale-up activities for A83B4C63, the Company's proprietary PNKP Inhibitor Technology. This phase of work is designed to refine and scale the synthesis process under non-GMP conditions as part of Onco's ongoing manufacturing development program, supporting future clinical material production. Building on the manufacturing activities previously initiated by Dalton for preclinical testing material, the Company has now advanced to the optimization and intermediate-scale production (for research purposes) of A83B4C63. This next phase focuses on process scale-up and analytical method qualification, which is intended to ensure a robust, reproducible, and scalable manufacturing process suitable for future GMP production and subsequent manufacturing of clinical material to support Onco's IND enabling and Phase 1 studies. The work will be performed using dedicated pilot-scale equipment at Dalton's FDA- and Health Canada-approved facility in Toronto, Canada. As part of this optimization phase, Dalton will conduct intermediary scale-up batches targeting approximately 500 g of precursor A83 and 1,000 g of precursor B4 to evaluate reaction performance under scale-up conditions in preparation for pre-clinical production of A 83B4C63. The A83B4C63 active pharmaceutical ingredient (API) will be used to support the development of Onco's encapsulated nanoparticle micelle formulation, which is designed with the goal of enhancing tumor-targeted delivery of the PNKP inhibitor, and with the ultimate goal of potentially improving therapeutic efficacy in cancer treatment. The manufacturing program also includes comprehensive analytical method development and stability testing conducted in accordance with International Council for Harmonisation (ICH) guidelines, as well as a formal safety and risk assessment of A83B4C 63 prior to full-scale synthesis. The optimization work encompasses precursor synthesis refinement, process scale-up, and analytical method development in accordance with international quality standards to ensure a robust and reproducible manufacturing process suitable for future GM PNKP production.공시 • Oct 31Onco-Innovations Limited Announces Board of Directors ChangesOnco-Innovations Limited announced the appointment of Mr. Jared Rushton to its Board of Directors, effective 31 October 2025. Mr. Rushton brings over a decade of experience in the public markets, with a strong background in corporate development, strategic advisory, and capital markets planning. Throughout his career, he has worked closely with emerging and growth-stage companies to support financing initiatives, investor engagement, market positioning, and operational execution. His diverse industry experience spans the mining, cannabis, and biotech and health sciences sectors, where he has played a key role in evaluating strategic opportunities, structuring partnerships, and guiding long-term growth strategies. Mr. Rushton has also advised on go-public transactions, corporate restructuring, and business development programs designed to enhance corporate value and strengthen shareholder alignment. Mr. Rushton replaces Mr. Zachary Stadnyk, who has stepped down from the Board. The Company extends its gratitude to Mr. Stadnyk for his dedication and contributions during his tenure.공시 • Oct 28Onco-Innovations Limited announced that it has received CAD 1.999998 million in fundingOn October 27, 2028, Onco-Innovations Limited closed the transaction. The company announced that it has issued 1,428,570 units at a price of CAD 1.40 per Unit, for aggregate gross proceeds of CAD 1,999,998. Each Unit consists of one common share and one-half of one common share purchase warrant, with each Warrant entitling the holder to purchase one Share at a price of CAD 2.00 for a period of thirty-six (36) months. In connection with the closing of the Private Placement, the Company paid, in aggregate, CAD 119,999.94 and issued 85,714 Warrants to certain finders in consideration for their introducing subscribers. The Company has also issued 14,286 Shares (“Administrative Shares”) of the Company to an arm’s-length third party, in consideration for administrative services rendered in connection with the Private Placement.공시 • Oct 15Onco-Innovations Limited announced that it expects to receive CAD 2.000001 million in fundingOnco-Innovations Limited announced a non-brokered private placement to issue 1,428,572 units at an issue price of CAD 1.40 for gross proceeds of CAD 2,000,000.8 on October 14, 2025. Each unit shall consist of one common share and one-half of one common share purchase warrant, with each Warrant entitling the holder to purchase one share at an exercise price of CAD 2 for a period of thirty-six months. The company also intends to issue shares equal to 1% of the total of shares issued in the private placement to an arm’s-length third party, as an administrative fee for their assistance with the private placement. In connection with the private placement, the company may pay finders’ fees and/or issue finders’ warrants on the same terms as the warrants, to eligible parties who have assisted by introducing subscribers to the private placement. Closing of the private placement is subject to certain conditions, including, but not limited to, the receipt of all necessary regulatory and other approvals. All securities issued pursuant to Private Placement will be subject to a hold period of four months and one day pursuant to applicable securities laws.공시 • Sep 23Onco Innovations Appoints Michael Lock to Scientific & Clinical Advisory BoardOnco-Innovations Limited announced the appointment of Dr. Michael Lock, Professor in the Department of Oncology and the Department of Medical Biophysics at the University of Western Ontario, to its Scientific and Clinical Advisory Board. Dr. Lock's expertise in clinical trial design, translational oncology, and multidisciplinary cancer care will support Onco in its development of novel therapies, including its PNKP inhibitor program. Dr. Lock is a Professor at Western University in the Department of Oncology and the Department of Medical Biophysics. He is a staff radiation oncologist who trained at Princess Margaret Hospital, University of Toronto, McMaster University, and the University of Wisconsin. Over his career, he has held leadership roles as Chair of the Department of Radiation Oncology, Chief of Division of Radiation Oncology, Medical Director of the London Regional Cancer Program, and Southwest Regional Radiation Oncology Lead. His experience spans clinical operations, trial oversight, and strategic program development across multiple oncology subspecialties. He has chaired and co-chaired several multidisciplinary site teams, including Breast Cancer, Genitourinary, and Hepatobiliary programs, ensuring integration of clinical research into patient care. Dr. Lock also served as Chair of the Radiation Oncology Provincial Advisory Committee, where he helped shape provincial priorities that established protocols and infrastructure that will serve patients for many years to come. He is an Associate Scientist with the Lawson Health Research Institute. His leadership in clinical trial methodology, coupled with his ability to align diverse research teams, will be highly relevant to Onco's translational and clinical pipeline. In addition to his work in Canada, Dr. Lock has contributed to advancing cancer care globally through collaborations with the International Atomic Energy Agency (IAEA), the United Nations (UN), and the World Health Organization (WHO). He has received multiple recognitions, including the Human Touch Award and the MAC Administrative Award, for his leadership and contributions to oncology.공시 • Sep 06Onco-Innovations Limited Announces the Appointment of Dr. John Mackey to Its Scientific and Clinical Advisory BoardOnco-Innovations Limited announce the appointment of Dr. John Mackey, Professor Emeritus in the Department of Oncology at the University of Alberta, to its Scientific and Clinical Advisory Board. His expertise will support Onco's efforts in aligning translational research with clinical execution, particularly as the Company progresses toward later-stage development of its PNKP inhibitor program. Dr. Mackey has extensive experience in oncology, clinical trials, and cancer drug development. He previously served as Director of the Clinical Trial Unit at the Cross Cancer Institute and as Executive Director of Translational Research in Oncology (TRIO), a not-for-profit academic clinical research organization responsible for interventional cancer trials involving more than 22,000 participants1 globally. He is a co-founder of Pacylex Pharmaceuticals, a biotechnology company developing therapies targeting N-myristoyl transferases, currently in Phase II international trials. He is also the CEO of illumiSonics, which is developing Microcellular Laser Imaging (MLI) technology for molecular histology. Additional initiatives include founding SMHeartCard, a personal emergency medication carriage system, and co-developing CWTA, a statistical method for analyzing multiple health states in clinical trials. Across these ventures, Dr. Mackey has been directly involved in advancing novel therapies from early-stage development through to clinical evaluation and commercialization, providing relevant experience for Onco's translational and commercial ambitions. Dr. Mackey holds 12 patents and has co-authored over 300 peer-reviewed publications covering a range of topics, including membrane transporter biochemistry, oncology clinical trials, cancer diagnostics, physical activity as an intervention for cancer patients, and statistical methodologies. He is a Fellow of the Canadian Academy of Health Sciences. In his role on the Scientific &Clinical Advisory Board, Dr. Mackey will contribute his expertise in clinical development, trial methodology, and translational oncology. His responsibilities will include advising on clinical strategy related to the Company's PNKP Inhibitor Technology (NP/A83) and other ongoing research programs.공시 • Aug 14Onco-Innovations Limited announced that it has received CAD 0.400001 million in fundingOn August 13, 2025. Onco-Innovations Limited announced that it has closed the transaction. It has issued 243,903 units at a price of CAD 1.64 per unit for proceeds of CAD 400,000.92.공시 • Jul 30Onco-Innovations Limited announced that it expects to receive CAD 0.400001 million in fundingOnco-Innovations Limited announces a non-brokered private placement to issue 243,903 units at a price of CAD 1.64 per unit for gross proceeds of CAD 400,000.92 on July 29, 2025. Each Unit shall consist of one common share and one Share purchase warrant, with each Warrant entitling the holder to purchase one Share at an exercise price of CAD 2.05 for a period of 36 months. All securities issued pursuant to Private Placement will be subject to a hold period of four months and one day pursuant to applicable securities laws.공시 • Jul 11Onco-Innovations Limited Announces Appointment of Dr. Islam Mohamed as Chair of Its Scientific and Clinical Advisory BoardOnco-Innovations Limited announced the appointment of Dr. Islam Mohamed as Chair of Its Scientific and Clinical Advisory Board. This appointment reflects the Company's commitment to scientific excellence and its mission to accelerate the development of innovative oncology solutions through expert-led translational research. Dr. Islam Mohamed is an experienced Radiation Oncologist, clinical researcher, and biotechnology advisor who has spent over two decades operating at the intersection of oncology and innovation. After earning an Honours BSc in Genetics, he pursued a career in Medicine, completing his specialty training in Radiation Oncology in 2000. At BC Cancer, he has built a distinguished clinical career focused on lung, breast, skin cancers, and sarcoma, and is recognized for his expertise in stereotactic radiation delivery. Dr. Mohamed has led numerous clinical trials at both local and provincial levels, contributing to advances in the treatment of breast, lung, and oligometastatic cancers. He has also served on research ethics boards and national clinical trial committees, shaping standards of care and clinical research strategy in Canada. Complementing his clinical leadership, Dr. Mohamed brings deep insight into the health technology ecosystem. He advises and invests in emerging Canadian biotech ventures, including Linax Technologies, IllumiSonics, and Asep Medical, with a focus on companies developing transformative diagnostics, therapeutics, and platform technologies. His combined experience as a clinician, researcher, and entrepreneur positions him as a strategic asset in evaluating innovation, guiding translational research, and driving value creation. The Scientific and Clinical Advisory Board plays a critical role in supporting Onco-Innovations' research and development (R&D) priorities. Its mandate is to provide strategic guidance on R&D initiatives, facilitate clinical and scientific collaboration among partners, and support the mobilization of knowledge and generation of independent scientific insights to guide decision-making.공시 • Jun 17Onco-Innovations Limited, Annual General Meeting, Aug 12, 2025Onco-Innovations Limited, Annual General Meeting, Aug 12, 2025.공시 • May 01Onco-Innovations Limited announced that it has received CAD 0.6 million in fundingOn April 30, 2025 Onco-Innovations Limited closed the transaction and issue 400,000 units at an issue price of CAD 1.50 per unit for gross proceeds of CAD 600,000. Each unit consists of one common share and one common share purchase warrant, with each warrant entitling the holder to purchase one share at an exercise price of CAD 1.60 for a period of 36 months expiring April 30, 2028. The company has also issued 4,000 shares at a deemed price of CAD 1.50 per administrative share of the company to an arm's-length third party in consideration for administrative services rendered in connection with the private placement. Pursuant to applicable securities laws, all securities issued under the private placement and the administrative shares will be subject to a statutory hold period of four months and one day, expiring on Aug. 31, 2025.공시 • Apr 17Onco-Innovations Limited announced that it expects to receive CAD 0.6 million in fundingOnco-Innovations Limited announced a non-brokered private placement to issue 400,000 units at an issue price of CAD 1.50 per unit for gross proceeds of CAD 600,000 on April 16, 2025. Each Unit shall consist of one common share and one common share purchase warrant, with each (whole) Warrant entitling the holder to purchase one Share at an exercise price of CAD 1.60 for a period of 36 months. Closing of the Private Placement is anticipated to occur on or about April 25, 2025, and is subject to certain conditions, including, but not limited to, the receipt of all necessary regulatory and other approvals. All securities issued pursuant to Private Placement will be subject to a hold period of four months and one day pursuant to applicable securities laws.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 ONNV.F 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: ONNV.F 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Onco-Innovations 배당 수익률 vs 시장ONNV.F의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (ONNV.F)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Biotechs)2.4%분석가 예측 (ONNV.F) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 ONNV.F 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 ONNV.F 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 ONNV.F 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: ONNV.F 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/29 22:36종가2026/05/29 00:00수익2026/01/31연간 수익2025/04/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Onco-Innovations Limited는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Jan 25Onco-Innovations Limited announced that it expects to receive CAD 2 million in fundingOnco-Innovations Limited announced a non-brokered private placement of up to 2,272,727 units at a price of CAD 0.88 per unit for aggregate gross proceeds of up to CAD 1,999,999.76 on January 23, 2026. Each unit shall consist of one common share and one-half of one common share purchase warrant, with each warrant entitling the holder to purchase one share at an exercise price of CAD 1.10 for a period of 36 months. The company also intends to issue shares equal to 1% of the total of shares issued in the private placement to an arm's-length third party as an administrative fee for its assistance with the private placement. In connection with the private placement, the company may pay finders' fees and/or issue finders' warrants on the same terms as the warrants to eligible parties which have assisted by introducing subscribers to the private placement. Closing of the private placement is subject to certain conditions, including, but not limited to, the receipt of all necessary regulatory and other approvals. All securities issued pursuant to the private placement will be subject to a hold period of four months and one day pursuant to applicable securities laws.
공시 • Nov 22Onco-Innovations Advances Optimization and Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services to Support Future Phase 1 Clinical StudiesOnco-Innovations Limited announced that its manufacturing partner, Dalton Pharma Services ("Dalton"), has initiated process optimization and intermediate scale-up activities for A83B4C63, the Company's proprietary PNKP Inhibitor Technology. This phase of work is designed to refine and scale the synthesis process under non-GMP conditions as part of Onco's ongoing manufacturing development program, supporting future clinical material production. Building on the manufacturing activities previously initiated by Dalton for preclinical testing material, the Company has now advanced to the optimization and intermediate-scale production (for research purposes) of A83B4C63. This next phase focuses on process scale-up and analytical method qualification, which is intended to ensure a robust, reproducible, and scalable manufacturing process suitable for future GMP production and subsequent manufacturing of clinical material to support Onco's IND enabling and Phase 1 studies. The work will be performed using dedicated pilot-scale equipment at Dalton's FDA- and Health Canada-approved facility in Toronto, Canada. As part of this optimization phase, Dalton will conduct intermediary scale-up batches targeting approximately 500 g of precursor A83 and 1,000 g of precursor B4 to evaluate reaction performance under scale-up conditions in preparation for pre-clinical production of A 83B4C63. The A83B4C63 active pharmaceutical ingredient (API) will be used to support the development of Onco's encapsulated nanoparticle micelle formulation, which is designed with the goal of enhancing tumor-targeted delivery of the PNKP inhibitor, and with the ultimate goal of potentially improving therapeutic efficacy in cancer treatment. The manufacturing program also includes comprehensive analytical method development and stability testing conducted in accordance with International Council for Harmonisation (ICH) guidelines, as well as a formal safety and risk assessment of A83B4C 63 prior to full-scale synthesis. The optimization work encompasses precursor synthesis refinement, process scale-up, and analytical method development in accordance with international quality standards to ensure a robust and reproducible manufacturing process suitable for future GM PNKP production.
공시 • Oct 31Onco-Innovations Limited Announces Board of Directors ChangesOnco-Innovations Limited announced the appointment of Mr. Jared Rushton to its Board of Directors, effective 31 October 2025. Mr. Rushton brings over a decade of experience in the public markets, with a strong background in corporate development, strategic advisory, and capital markets planning. Throughout his career, he has worked closely with emerging and growth-stage companies to support financing initiatives, investor engagement, market positioning, and operational execution. His diverse industry experience spans the mining, cannabis, and biotech and health sciences sectors, where he has played a key role in evaluating strategic opportunities, structuring partnerships, and guiding long-term growth strategies. Mr. Rushton has also advised on go-public transactions, corporate restructuring, and business development programs designed to enhance corporate value and strengthen shareholder alignment. Mr. Rushton replaces Mr. Zachary Stadnyk, who has stepped down from the Board. The Company extends its gratitude to Mr. Stadnyk for his dedication and contributions during his tenure.
공시 • Oct 28Onco-Innovations Limited announced that it has received CAD 1.999998 million in fundingOn October 27, 2028, Onco-Innovations Limited closed the transaction. The company announced that it has issued 1,428,570 units at a price of CAD 1.40 per Unit, for aggregate gross proceeds of CAD 1,999,998. Each Unit consists of one common share and one-half of one common share purchase warrant, with each Warrant entitling the holder to purchase one Share at a price of CAD 2.00 for a period of thirty-six (36) months. In connection with the closing of the Private Placement, the Company paid, in aggregate, CAD 119,999.94 and issued 85,714 Warrants to certain finders in consideration for their introducing subscribers. The Company has also issued 14,286 Shares (“Administrative Shares”) of the Company to an arm’s-length third party, in consideration for administrative services rendered in connection with the Private Placement.
공시 • Oct 15Onco-Innovations Limited announced that it expects to receive CAD 2.000001 million in fundingOnco-Innovations Limited announced a non-brokered private placement to issue 1,428,572 units at an issue price of CAD 1.40 for gross proceeds of CAD 2,000,000.8 on October 14, 2025. Each unit shall consist of one common share and one-half of one common share purchase warrant, with each Warrant entitling the holder to purchase one share at an exercise price of CAD 2 for a period of thirty-six months. The company also intends to issue shares equal to 1% of the total of shares issued in the private placement to an arm’s-length third party, as an administrative fee for their assistance with the private placement. In connection with the private placement, the company may pay finders’ fees and/or issue finders’ warrants on the same terms as the warrants, to eligible parties who have assisted by introducing subscribers to the private placement. Closing of the private placement is subject to certain conditions, including, but not limited to, the receipt of all necessary regulatory and other approvals. All securities issued pursuant to Private Placement will be subject to a hold period of four months and one day pursuant to applicable securities laws.
공시 • Sep 23Onco Innovations Appoints Michael Lock to Scientific & Clinical Advisory BoardOnco-Innovations Limited announced the appointment of Dr. Michael Lock, Professor in the Department of Oncology and the Department of Medical Biophysics at the University of Western Ontario, to its Scientific and Clinical Advisory Board. Dr. Lock's expertise in clinical trial design, translational oncology, and multidisciplinary cancer care will support Onco in its development of novel therapies, including its PNKP inhibitor program. Dr. Lock is a Professor at Western University in the Department of Oncology and the Department of Medical Biophysics. He is a staff radiation oncologist who trained at Princess Margaret Hospital, University of Toronto, McMaster University, and the University of Wisconsin. Over his career, he has held leadership roles as Chair of the Department of Radiation Oncology, Chief of Division of Radiation Oncology, Medical Director of the London Regional Cancer Program, and Southwest Regional Radiation Oncology Lead. His experience spans clinical operations, trial oversight, and strategic program development across multiple oncology subspecialties. He has chaired and co-chaired several multidisciplinary site teams, including Breast Cancer, Genitourinary, and Hepatobiliary programs, ensuring integration of clinical research into patient care. Dr. Lock also served as Chair of the Radiation Oncology Provincial Advisory Committee, where he helped shape provincial priorities that established protocols and infrastructure that will serve patients for many years to come. He is an Associate Scientist with the Lawson Health Research Institute. His leadership in clinical trial methodology, coupled with his ability to align diverse research teams, will be highly relevant to Onco's translational and clinical pipeline. In addition to his work in Canada, Dr. Lock has contributed to advancing cancer care globally through collaborations with the International Atomic Energy Agency (IAEA), the United Nations (UN), and the World Health Organization (WHO). He has received multiple recognitions, including the Human Touch Award and the MAC Administrative Award, for his leadership and contributions to oncology.
공시 • Sep 06Onco-Innovations Limited Announces the Appointment of Dr. John Mackey to Its Scientific and Clinical Advisory BoardOnco-Innovations Limited announce the appointment of Dr. John Mackey, Professor Emeritus in the Department of Oncology at the University of Alberta, to its Scientific and Clinical Advisory Board. His expertise will support Onco's efforts in aligning translational research with clinical execution, particularly as the Company progresses toward later-stage development of its PNKP inhibitor program. Dr. Mackey has extensive experience in oncology, clinical trials, and cancer drug development. He previously served as Director of the Clinical Trial Unit at the Cross Cancer Institute and as Executive Director of Translational Research in Oncology (TRIO), a not-for-profit academic clinical research organization responsible for interventional cancer trials involving more than 22,000 participants1 globally. He is a co-founder of Pacylex Pharmaceuticals, a biotechnology company developing therapies targeting N-myristoyl transferases, currently in Phase II international trials. He is also the CEO of illumiSonics, which is developing Microcellular Laser Imaging (MLI) technology for molecular histology. Additional initiatives include founding SMHeartCard, a personal emergency medication carriage system, and co-developing CWTA, a statistical method for analyzing multiple health states in clinical trials. Across these ventures, Dr. Mackey has been directly involved in advancing novel therapies from early-stage development through to clinical evaluation and commercialization, providing relevant experience for Onco's translational and commercial ambitions. Dr. Mackey holds 12 patents and has co-authored over 300 peer-reviewed publications covering a range of topics, including membrane transporter biochemistry, oncology clinical trials, cancer diagnostics, physical activity as an intervention for cancer patients, and statistical methodologies. He is a Fellow of the Canadian Academy of Health Sciences. In his role on the Scientific &Clinical Advisory Board, Dr. Mackey will contribute his expertise in clinical development, trial methodology, and translational oncology. His responsibilities will include advising on clinical strategy related to the Company's PNKP Inhibitor Technology (NP/A83) and other ongoing research programs.
공시 • Aug 14Onco-Innovations Limited announced that it has received CAD 0.400001 million in fundingOn August 13, 2025. Onco-Innovations Limited announced that it has closed the transaction. It has issued 243,903 units at a price of CAD 1.64 per unit for proceeds of CAD 400,000.92.
공시 • Jul 30Onco-Innovations Limited announced that it expects to receive CAD 0.400001 million in fundingOnco-Innovations Limited announces a non-brokered private placement to issue 243,903 units at a price of CAD 1.64 per unit for gross proceeds of CAD 400,000.92 on July 29, 2025. Each Unit shall consist of one common share and one Share purchase warrant, with each Warrant entitling the holder to purchase one Share at an exercise price of CAD 2.05 for a period of 36 months. All securities issued pursuant to Private Placement will be subject to a hold period of four months and one day pursuant to applicable securities laws.
공시 • Jul 11Onco-Innovations Limited Announces Appointment of Dr. Islam Mohamed as Chair of Its Scientific and Clinical Advisory BoardOnco-Innovations Limited announced the appointment of Dr. Islam Mohamed as Chair of Its Scientific and Clinical Advisory Board. This appointment reflects the Company's commitment to scientific excellence and its mission to accelerate the development of innovative oncology solutions through expert-led translational research. Dr. Islam Mohamed is an experienced Radiation Oncologist, clinical researcher, and biotechnology advisor who has spent over two decades operating at the intersection of oncology and innovation. After earning an Honours BSc in Genetics, he pursued a career in Medicine, completing his specialty training in Radiation Oncology in 2000. At BC Cancer, he has built a distinguished clinical career focused on lung, breast, skin cancers, and sarcoma, and is recognized for his expertise in stereotactic radiation delivery. Dr. Mohamed has led numerous clinical trials at both local and provincial levels, contributing to advances in the treatment of breast, lung, and oligometastatic cancers. He has also served on research ethics boards and national clinical trial committees, shaping standards of care and clinical research strategy in Canada. Complementing his clinical leadership, Dr. Mohamed brings deep insight into the health technology ecosystem. He advises and invests in emerging Canadian biotech ventures, including Linax Technologies, IllumiSonics, and Asep Medical, with a focus on companies developing transformative diagnostics, therapeutics, and platform technologies. His combined experience as a clinician, researcher, and entrepreneur positions him as a strategic asset in evaluating innovation, guiding translational research, and driving value creation. The Scientific and Clinical Advisory Board plays a critical role in supporting Onco-Innovations' research and development (R&D) priorities. Its mandate is to provide strategic guidance on R&D initiatives, facilitate clinical and scientific collaboration among partners, and support the mobilization of knowledge and generation of independent scientific insights to guide decision-making.
공시 • Jun 17Onco-Innovations Limited, Annual General Meeting, Aug 12, 2025Onco-Innovations Limited, Annual General Meeting, Aug 12, 2025.
공시 • May 01Onco-Innovations Limited announced that it has received CAD 0.6 million in fundingOn April 30, 2025 Onco-Innovations Limited closed the transaction and issue 400,000 units at an issue price of CAD 1.50 per unit for gross proceeds of CAD 600,000. Each unit consists of one common share and one common share purchase warrant, with each warrant entitling the holder to purchase one share at an exercise price of CAD 1.60 for a period of 36 months expiring April 30, 2028. The company has also issued 4,000 shares at a deemed price of CAD 1.50 per administrative share of the company to an arm's-length third party in consideration for administrative services rendered in connection with the private placement. Pursuant to applicable securities laws, all securities issued under the private placement and the administrative shares will be subject to a statutory hold period of four months and one day, expiring on Aug. 31, 2025.
공시 • Apr 17Onco-Innovations Limited announced that it expects to receive CAD 0.6 million in fundingOnco-Innovations Limited announced a non-brokered private placement to issue 400,000 units at an issue price of CAD 1.50 per unit for gross proceeds of CAD 600,000 on April 16, 2025. Each Unit shall consist of one common share and one common share purchase warrant, with each (whole) Warrant entitling the holder to purchase one Share at an exercise price of CAD 1.60 for a period of 36 months. Closing of the Private Placement is anticipated to occur on or about April 25, 2025, and is subject to certain conditions, including, but not limited to, the receipt of all necessary regulatory and other approvals. All securities issued pursuant to Private Placement will be subject to a hold period of four months and one day pursuant to applicable securities laws.